Biogen 관리
관리 기준 확인 4/4
현재 CEO에 대한 정보가 충분하지 않습니다.
주요 정보
Chris Viehbacher
최고 경영자
US$4.1m
총 보상
CEO 급여 비율 | 39.3% |
CEO 임기 | 2yrs |
CEO 소유권 | 0.005% |
경영진 평균 재임 기간 | 4.5yrs |
이사회 평균 재임 기간 | 4.4yrs |
최근 관리 업데이트
Recent updates
Biogen Q3 Earnings Review: Why I Remain Optimistic Despite Difficult Quarter
Oct 31Does Biogen (NASDAQ:BIIB) Have A Healthy Balance Sheet?
Oct 01What You Can Learn From Biogen Inc.'s (NASDAQ:BIIB) P/E
Sep 04Biogen: Q2 Earnings, Share Price May Have Bottomed Out As CEO Makes Mark
Aug 17Biogen Stock: Cheapish, But With Few Growth Prospects
Jul 11Is Biogen (NASDAQ:BIIB) Using Too Much Debt?
May 23Biogen's Revenue Dip Meets Cost Cuts In Q1 (Rating Upgrade)
Apr 29Earnings Update: Biogen Inc. (NASDAQ:BIIB) Just Reported Its First-Quarter Results And Analysts Are Updating Their Forecasts
Apr 28The Price Is Right For Biogen Inc. (NASDAQ:BIIB)
Apr 15We Think You Can Look Beyond Biogen's (NASDAQ:BIIB) Lackluster Earnings
Feb 21Biogen Inc. Just Missed EPS By 21%: Here's What Analysts Think Will Happen Next
Feb 16Biogen's Q4 Earnings Disappoint Amidst Strategic Challenges (Rating Downgrade)
Feb 14Here's Why Biogen (NASDAQ:BIIB) Can Manage Its Debt Responsibly
Jan 31Biotech And Pharma Diversification Pays Off
Jan 25Getting In Cheap On Biogen Inc. (NASDAQ:BIIB) Might Be Difficult
Dec 26An Intrinsic Calculation For Biogen Inc. (NASDAQ:BIIB) Suggests It's 49% Undervalued
Oct 21Is Biogen (NASDAQ:BIIB) Using Too Much Debt?
Oct 03Is Biogen Inc. (NASDAQ:BIIB) Trading At A 31% Discount?
Jul 16Biogen (NASDAQ:BIIB) Has A Pretty Healthy Balance Sheet
Jun 28CEO 보상 분석
날짜 | 총 보상 | 급여 | 회사 수익 |
---|---|---|---|
Sep 30 2024 | n/a | n/a | US$2b |
Jun 30 2024 | n/a | n/a | US$1b |
Mar 31 2024 | n/a | n/a | US$1b |
Dec 31 2023 | US$4m | US$2m | US$1b |
Sep 30 2023 | n/a | n/a | US$1b |
Jun 30 2023 | n/a | n/a | US$3b |
Mar 31 2023 | n/a | n/a | US$3b |
Dec 31 2022 | US$30m | US$154k | US$3b |
보상 대 시장: Chris 의 총 보상 ($USD 4.07M ) US 시장에서 비슷한 규모의 회사에 대한 평균보다 낮습니다( $USD 12.87M ).
보상과 수익: Chris 의 보상은 지난 한 해 동안 회사 성과와 일치했습니다.
CEO
Chris Viehbacher (63 yo)
2yrs
테뉴어
US$4,069,913
보상
Mr. Christopher A. Viehbacher, also known as Chris, is Director of Innocoll Holdings plc from July 24, 2017. He joined the Innocoll Holdings plc on July 24, 2017. He serves as President, Chief Executive Of...
리더십 팀
이름 | 위치 | 테뉴어 | 보상 | 소유권 |
---|---|---|---|---|
President | 2yrs | US$4.07m | 0.0048% $ 1.2m | |
Executive VP & CFO | 4.3yrs | US$7.17m | 0.013% $ 3.4m | |
Head of Pharmaceutical Operations & Technology | 2.8yrs | US$5.71m | 0.0066% $ 1.7m | |
Executive VP & Chief Legal Officer | 18.8yrs | US$6.70m | 0.035% $ 9.0m | |
Head of Global Product Strategy & Commercialization | 3.8yrs | US$5.45m | 0.0067% $ 1.7m | |
Senior VP & Chief Accounting Officer | 6yrs | 데이터 없음 | 0.0043% $ 1.1m | |
Head of Investor Relations | less than a year | 데이터 없음 | 데이터 없음 | |
Chief Communication Officer & Head of Corporate Affairs | 4.8yrs | 데이터 없음 | 데이터 없음 | |
Executive VP & Head of Corporate Development | 1.6yrs | 데이터 없음 | 0.00045% $ 114.0k | |
Executive VP & Chief Human Resources Officer | 7.3yrs | US$5.08m | 0.0093% $ 2.4m | |
President & Head of North America | 7.3yrs | 데이터 없음 | 데이터 없음 | |
Head of Biotherapeutics & Medicinal Sciences | 7.3yrs | 데이터 없음 | 데이터 없음 |
4.5yrs
평균 재임 기간
58yo
평균 연령
경험이 풍부한 관리: BIIB 의 관리팀은 경험 ( 4.5 년 평균 재직 기간)으로 간주됩니다.
이사회 구성원
이름 | 위치 | 테뉴어 | 보상 | 소유권 |
---|---|---|---|---|
President | 2yrs | US$4.07m | 0.0048% $ 1.2m | |
Independent Director | 14.7yrs | US$435.32k | 0.013% $ 3.3m | |
Independent Director | 5.4yrs | US$425.73k | 0.0044% $ 1.1m | |
Independent Chair of the Board | 14.8yrs | US$646.13k | 0.017% $ 4.3m | |
Independent Director | 14.7yrs | US$418.02k | 0.014% $ 3.6m | |
Independent Director | 3.4yrs | US$412.90k | 0.0031% $ 772.4k | |
Directors | less than a year | 데이터 없음 | 데이터 없음 | |
Independent Director | less than a year | 데이터 없음 | 0.00092% $ 233.0k | |
Independent Director | 5.4yrs | US$433.23k | 0.0051% $ 1.3m | |
Independent Director | 1.4yrs | US$334.53k | 0.0019% $ 478.6k |
4.4yrs
평균 재임 기간
65yo
평균 연령
경험이 풍부한 이사회: BIIB 의 이사회는 경험(평균 재직 기간 4.4 년)으로 간주됩니다.